ARTICLE | Clinical News
Azilect rasagiline regulatory update
June 30, 2014 7:00 AM UTC
FDA approved an sNDA for Azilect rasagiline to include use as an adjunct to dopamine agonists to treat Parkinson’s disease. The irreversible selective inhibitor of monoamine oxidase B (MAO-B) is alre...